MediciNova to Present at H.C. Wainwright Global Investment Conference
ByAinvest
Wednesday, Sep 3, 2025 7:05 am ET1min read
MNOV--
The conference, scheduled from September 8 to 10, 2025, at the Lotte New York Palace Hotel, will feature a live webcast of the presentation available on-demand beginning at 7:00am ET on September 5, 2025. The webcast can be accessed via the investor relations section of the MediciNova website, with a replay archived for approximately 90 days [1].
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Its lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM), and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials for Long COVID and substance dependence. Another key compound, MN-001 (tipelukast), was evaluated in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF), with a second Phase 2 trial ongoing for non-alcoholic fatty liver disease (NAFLD) [1].
Drs. Iwaki and Crean will be available for one-on-one meetings throughout the conference. Interested parties can register for the event and request meetings via the H.C. Wainwright conference website [1].
References:
[1] https://www.marketscreener.com/news/medicinova-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference-ce7d59dad180fe23
MediciNova, a biopharmaceutical company, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. Yuichi Iwaki, President and CEO, and David Crean, Chief Business Officer, will present on September 5, 2025. The presentation will be available on-demand and can be accessed on the MediciNova website. Drs. Iwaki and Crean will be available for one-on-one meetings throughout the conference.
MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will be delivered by Yuichi Iwaki, MD., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, on September 5, 2025 [1].The conference, scheduled from September 8 to 10, 2025, at the Lotte New York Palace Hotel, will feature a live webcast of the presentation available on-demand beginning at 7:00am ET on September 5, 2025. The webcast can be accessed via the investor relations section of the MediciNova website, with a replay archived for approximately 90 days [1].
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Its lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM), and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials for Long COVID and substance dependence. Another key compound, MN-001 (tipelukast), was evaluated in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF), with a second Phase 2 trial ongoing for non-alcoholic fatty liver disease (NAFLD) [1].
Drs. Iwaki and Crean will be available for one-on-one meetings throughout the conference. Interested parties can register for the event and request meetings via the H.C. Wainwright conference website [1].
References:
[1] https://www.marketscreener.com/news/medicinova-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference-ce7d59dad180fe23
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet